Drug Description in Trials / DrugBank / KEGG DRUG


Search results


No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1Other: Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq
(D11243)
[8] Alemtuzumab,
Cladribine,
Hyaluronidase,
Natalizumab,
Ocrelizumab,
Ofatumumab,
Rituximab,
Ublituximab
[10] Cladribine ,
Alemtuzumab ,
Rituximab ,
Hyaluronidase ,
Hyaluronidase ,
Ocrelizumab ,
Hyaluronidase ,
Natalizumab ,
Ofatumumab ,
Ublituximab (D11243) 💬
[3] ITGA4,
MS4A1,
RRM1 💬
[21] Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecule (CAM) interaction, Cytoskeleton in muscle cells, Dilated cardiomyopathy, Drug metabolism - other enzymes, ECM-receptor interaction, Focal adhesion, Glutathione metabolism, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, IgSF CAM signaling, Integrin signaling, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Purine metabolism, Pyrimidine metabolism, Regulation of actin cytoskeleton, Yersinia infection 💬[1] 13 💬
2UBLITUXIMAB
(D11243)
[1] Ublituximab[1] Ublituximab (D11243) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬